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Abstract: In recent years, the marine environment has been the subject of increasing attention from
biotechnological and pharmaceutical industries as a valuable and promising source of novel bioactive
compounds. Marine biodiscovery programmes have begun to reveal the extent of novel compounds
encoded within the enormous bacterial richness and diversity of the marine ecosystem. A combination
of unique physicochemical properties and spatial niche-specific substrates, in wide-ranging and
extreme habitats, underscores the potential of the marine environment to deliver on functionally
novel biocatalytic activities. With the growing need for green alternatives to industrial processes,
and the unique transformations which nature is capable of performing, marine biocatalysts have the
potential to markedly improve current industrial pipelines. Furthermore, biocatalysts are known to
possess chiral selectivity and specificity, a key focus of pharmaceutical drug design. In this review,
we discuss how the explosion in genomics based sequence analysis, allied with parallel developments
in synthetic and molecular biology, have the potential to fast-track the discovery and subsequent
improvement of a new generation of marine biocatalysts.
Keywords: synthetic biology; metagenomics; biocatalysis; marine; biodiscovery; chassis; vector;
heterologous expression
1. Introduction
With the oceanic ecosystem covering approximately 71% of the Earth’s surface, the marine
environment represents the largest and most promising aquatic reservoir of biodiversity on the planet.
The extent of this biodiversity, encompassing all orders of life, is already well established, making
the marine spatial niche one of the most abundant sources of natural richness on the face of the
planet [1–3]. The combination of species richness with the unique physicochemical properties offered
by the marine ecosystem (such as high osmolarity, broad range of different temperatures, and different
pH), allied with the extent of uncommon functional groups found in this environment (e.g., isonitrile,
dichloroimine, isocyanate, and halogenated functional groups), underpins the breadth of chemical
biodiversity in this biotechnologically important niche. Increasingly, there is growing evidence of
the promising potential of untapped bioactive compounds isolated from the marine ecosystem with
pharmaceutical and biotechnological applications [4].
In terms of phylogenetic and functional diversity, recent advances in molecular ecology,
metagenomic and ecological modelling depict microbial organisms as representing the most relevant
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biological group in the marine environment. Estimated at 104 to 106 cells per milliliter, microbial
biomass combined with environmental complexity and high turnover rates underpins the genetic
diversity of the oceanic microbiome [5]. Marine bacteria in particular have been reported to produce a
diverse array of secondary metabolites, with a proven benefit in human health [6,7]. More recently there
has been increasing interest in bioprospecting the marine environment for biocatalytics, not least due to
the likely presence of unique substrates within this ecosystem. By definition, biocatalysts are enzymes
from natural sources that modify the rate of a particular reaction. These can range from classical
enzymes such as lipases, proteases and nitrilases, to the modular enzymes involved in the synthesis of
complex natural products such as polyketide synthases (PKS) and Non-Ribosomal Peptide Synthases
(NRPSs). This latter class of biocatalyst has received considerable attention in light of the considerable
interest in natural products and their potential for chiral resolution. The physicochemical properties
required for many industrial transformations are consistent with those prevailing in the oceans,
promising compatibility with existing industrial processes [8,9]. The use of novel biocatalysts is not
only driven by their high versatility, but also owing to, the relevant intrinsic enzyme-associated features
such as, regio-, chemo-, and enantioselectivity, as well as, the clean and cost-effective mechanisms
that are represented by enzyme-catalyzed reactions [10]. These features, when implemented in
industrial processes, contribute to a reduction in toxic effluents and can markedly reduce costs [11].
Generally encoded as single transcripts, the transformation of natural and non-natural compounds
by microbially-derived enzymes (biocatalysis) represents a highly efficient and fruitful strategy
applied for the production of many valuable compounds within biotechnological and pharmaceutical
industries [10,12–14].
Current estimates put the market for biocatalysts at approximately US$4 billion [15] and the
extent of enzyme categories employed continues to expand. Nitrilases, proteases (used in detergents
and in pharmaceutical and chemical industries to degrade proteins into amino acids), lipases
(synthesis of fine chemicals), transaminases, and glycosyl hydrolases such as cellulases and xylanases
(paper and pulp industries) are among the most sought after activities. Many of these activities
also support conversion to biofuels, with glycosyl hydrolases particularly important in this regard.
Therefore, there is keen interest in developing biocatalysts for application in a diverse spectrum
of industrial processes. One aspect to that has been the biodiscovery of novel biocatalysts from
environmental samples using genomics based technologies. By virtue of their ability to inhabit
and persist in extreme and severe environments (e.g., glaciers [16]; Arctic soil [17] and deep-sea
hyper-saline brine pools [18]), the potential for microbes to deliver on novel biocatalytic functionality is
considerable [19,20]. Marine niches, although still largely unexplored, have already delivered abundant
diversity of novel microorganisms with unique functions [21]. In this regard, the extent to which
they encode novel biocatalytic activities would be a key determinant in the “hit rate” of prospective
mining studies.
A simple representative COG (clusters of orthologous groups) analysis of the available
metagenome datasets (IMG Database) reveals the marine ecotype as an abundant source of protease,
lipase, cellulase, transaminase and other industrially relevant biocatalytic activities, underpinning the
importance of this resource (Figure 1). A more comprehensive COG search of other interesting enzymes
is included in Supplementary File 1. While the relative abundance of COGs was found to be higher in
terrestrial ecosystems than in the aquatic environment, the terrestrial environment has already been
extensively mined for similar activities. Focusing on the aquatic environment, marine metagenomic
samples followed by freshwater samples represented the highest relative abundance of all eco-types for
all the different COGs assessed. Of the COGs analysed, three were particularly abundant in the aquatic
eco-category, namely COG1572 (protease), COG1496 (laccase) and COG4992 (transaminase). This fact,
linked to the presence of unique substrates available in the marine environment, reinforces the promise
of this diverse ecosystem as a source of novel biocatalysts. Of course, the relevance of this centres on
what constitutes the “ideal biocatalyst” [22,23]. Parameters such as activity, efficacy, specificity and
stability are key considerations in the selection of enzymes for different applications [24]. Enzymes
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with higher catalytic efficiency on insoluble substrates, increased stability at elevated temperature and
at defined pH, and higher tolerance to end-product inhibition are particularly sought after [25,26].
Until recently, the “best hit” derived from a microbial source, either culturable or non-culturable
would typically not have been a perfect fit with the industrial process or drug development pipeline.
Downstream manipulation using molecular tools would typically have been employed to adapt the
selected enzyme for the particular process requirements. With the advent of synthetic biology and the
development of improved biodiscovery tools, the “ideal biocatalyst” has become more of an attainable
goal than an aspiration. Key to this has been the explosion in genomic sequencing, the development of
annotation tools, and the refinement of the bioprospectors toolkit.
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Ecosystem (light blue). At Eco‐Category level, the most abundant Ecosystem is Terrestrial followed 
by Aquatic. Within Aquatic,  the highest  relative abundance of  the different COGs belongs  to  the 
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Within Aquatic, the highest relative abundance of the different COGs belongs to the Marine Eco-Type
(light purple) followed by Freshwater (green), supporting the biotechnological potential of the marine
as an alternative source of biocatalytic activity to the well explored terrestrial datasets.
Thus, in the present review we discuss the current genomic approaches, including the
identification, heterologous expression, and improvement of novel industrially relevant biocatalysts
from the marin environment. Covering b th culturable and non-culturable approaches,
a comprehensiv appraisal of the tools f r genomics based biocatalysis is prese t d. Subsequently,
the range of molecular to ls use for ioc talyst improvement are discussed, covering areas such as
directed evolution and synthetic biology.
2. Marine Environment as a Biocatalytic Reservoir
In the last decade, expeditions such as the Sorcerer II (2003–2010), the Malaspina (2010–2011),
and the Tara Oceans (2009–2013) have profiled the taxonomic and metagenomic content of the marine
ecosystem. Combining concerted global sampling efforts with high-capacity data analytics, we now
have unprecedented access to the structure and functionality of the marine microbiome [5,27,28].
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The breadth of microbial diversity encoded in the marine ecosystem is highlighted by the recent
TARA ocean expedition, which predicted more than 40 million novel genes from their sampling
programme [5]. Perhaps it is not surprising given that the marine ecosystem itself is subject to
extreme differences in environmental conditions, even within the same geographical area. In this sense,
from the Polar ocean and Polar coastal ecosystems, to the equatorial and hydrothermal equivalents,
microbial adaptation to these extreme environments is likely to underscore bioactivities with new
and commercially important properties. In this respect, of all of the organisms that inhabit extreme
environments, microorganisms are best placed to thrive under severe conditions that are too harsh
for animals, plants and other organisms too [29]. Extreme values of temperatures, pH, salinity,
oxido-reduction-potential, and also combinations thereof, are successfully tolerated by species of
marine microorganisms. According to Sarmiento and colleagues (2015), in many cases enzymes derived
from extreme habitats have undergone an adaptive process to withstand these severe conditions,
leading to changes in the secondary sequence and tertiary structure, flexibility, charge, and/or
hydrophobicity [30]. Therefore, the ecological resilience of the marine microorganisms in these extreme
environments may underpin their potential biotechnological applications. In light of the fact that the
vast majority of general industrial processes are conducted under harsh condition such as, acidic or
basic pHs, extremely low and high temperatures and elevated salinity, it is unsurprising that there has
been increased interest in these so called “extremoenzymes” [4,31,32]. There are some examples of
cold-adapted enzymes isolated from marine bacteria of great interest for diverse industrial markets,
such us, technical enzymes used in molecular biology, food and beverage and detergents, amongst
others. One example of a commercially available cold-adapted enzyme is the Antarctic Thermolabile
UDG (New England Biolabs), a recombinant Uracil-DNA N-glycosylase produced in E.coli derived
from a psychrophilic marine bacterium.
Of course, the genetic diversity and environmental complexity of the marine ecosystem in itself
does not necessarily mean that valuable and new biocatalytic activities will be encoded therein. Indeed,
the recent profiling of the marine microbiome performed by the Tara Oceans project reported that
73% of the core oceanic microbiome is shared with the human gut microbiome, in spite of the vastly
different physicochemical properties of both ecosystems [5]. Furthermore, despite a broad range of
fluctuating environmental parameters, temperature appears to be the dominant driver in shaping the
microbiome composition, at least in the sunlit epilagic ocean layer in which many sponge associated
communities exist [5]. However, it is important to consider that many of the novel and highly active
natural products that have been isolated from marine organisms have come from low abundant and
slow growing species. In fact, the role of the most abundant organisms within the microbiome is not
yet clear and the most abundant groups may not be the most active ones [33]. It is estimated that
marine species present double the chance of obtaining at least one gene in a patent than their terrestrial
counterparts [34], while the success rate in finding novel active chemicals in marine organisms is
500-fold higher than that for terrestrial species [35]. Therefore, the marine ecosystem is certainly worth
pursuing in the search for new and improved biocatalytics.
3. Biocatalysts as a Valuable Alternative to Traditional Chiral Chemical Synthesis
Thousands of natural chemical transformations are performed by diverse enzymes produced by
living organisms as part of their natural physiology, enabling growth and persistence in their respective
habitats. For some this can be the relatively hospitable nutrient rich environment of a compost heap
or fertile soil. For others it can be extreme as with hydrothermal vents of the ocean presenting
uniquely adapted enzymes for conversion of substrates to specific products [10]. Biocatalysts in
general, and marine biocatalysts in particular, have several advantages over non-biological catalysts.
The physicochemical properties, the presence of novel substrates and the breadth of diversity promised
by genomic sequencing from the marine environment, underscores the inherent features of biocatalysts
in general, such as their exquisitely precise chemo-, regio-, and stereocontrol. Moreover, catalysed
reactions often proceed both under mild and neutral aqueous conditions, circumventing the need
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for toxic organic solvents or heavy-metal catalysts, and in addition, by virtue of enzyme selectivity,
biocatalytic routes can preclude the need for synthetic protecting-group manipulations. However,
perhaps one of the most important features of biocatalysts is their capacity for the synthesis or
resolution of chiral molecules [36]. Through natural chirality of enzymes, most of the natural molecules
having stereogenic centers, such as, carbohydrates, nucleosides, amino acids, proteins, alkaloids
and hormones, are found in the single enantiomeric form. Thereby, nature creates and imposes
stereoselectivity by means of enzymes, which are highly efficient biocatalysts [37].
In all the biological systems, chirality is a ubiquitous feature that plays a very important
role in many and varied processes [38]. Chiral molecules exist when despite having identical
composition, the components of the molecule are arranged in a non-superimposable mirror image
composition, centred around an asymmetric carbon atom (Figure 2A). The two non-superimposable
mirror images of a chiral molecule are called enantiomers. Enantiomers show practically identical
physicochemical properties, and in many cases their biological activity can be similar. For example,
(+)-Aeroplysinin-1 was the first brominated derivate from the marine sponge Aplysina aerophoba
and the antibacterial activity of both stereoisomers was comparable [39]. However, this is not
always the case and many enantiomers or racemic drugs exhibit different functionalities in biological
systems [40]. One example of differences in the functionality of enantiomers is the case of Baclofen
(Figure 2A). Baclofen (4-amino-3-p-chlorophenylbutyric acid) is a chemical analogue of an inhibitory
neurotransmitter-γ-aminobutyric acid. Although marketed as a racemic mixture, the (R)-enantiomer
of baclofen is 100 times more active than the (S)-enantiomer. Furthermore, only the R-enantiomer
of baclofen is stereospecifically active at GAGAB-receptors [41]. In more extreme cases, toxic effects
of a particular enantiomer can manifest, as seen with the classic example of thalidomide. Another
example of this is salbutamol, best known as the active agent in inhalers. (R)-(´)-salbutamol (albuterol)
is responsible for bronchodilator effects. while (S)-(+)-salbutamol has little bronchodilating activity,
actually causes hyperkalemia, and has been implicated in eosinophil activation and pro-inflammatory
properties [42]. Therefore, both in terms of safety and efficacy, chirality is now a crucial factor of many
drug products and thus the production of single enantiomers of drug intermediates, as well as, drugs
themselves, is becoming increasingly important in the pharmaceutical industry [43].
To date, the main target has been to promote the chiral separation of interesting enantiomers,
as well as, the analysis of racemic drugs in the pharmacological area, avoiding or replacing enantiomers
that could play a less effective or negative role [44]. In the pharmacology field, the majority of
racemic drugs display an unequal activity of their enantiomers. This is the case for a number of
important drugs such as anticoagulants, antibiotics, proton pump inhibitors amongst others that
currently undergo chiral inversion or “chiral switch” to a more effective single-enantiomer version
(Figure 2B). Recent single enantiomers introduced to the market replacing racemic mixtures have been
(S)-Lansoprazole/(R)-Dexlansoprazole (a proton pump inhibitor) and (S)-Modafinil/(R)-Armodafinil
(a dopamine uptake inhibitor). S-enantiomers have been replaced in the market for their R-versions
due to their higher and more prolonged activity [44,45]. Similarly, chiral chemicals are also usually
required as key intermediates for the synthesis of a variety of pharmaceuticals, agrochemicals, food
ingredients, flavours, and fine chemicals [46].
Both, the breadth of use chiral synthesis and improvement of chiral separation methodologies,
as well as, the publication of the FDA’s policy statement for the development of new chiral drugs on
1992 (http://www.fda.gov/Drugs) [47], had contributed considerably to develop single-enantiomers
drugs by pharmaceutical manufacturers.
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It is ell established that conventional che ical synthesis routes to chiral products, are an
expensive alternative, that typically require harsh reaction conditions (such as elevated te perature,
high pressure, strongly basic or acidic conditions), which have a negative environ ental i pact.
Biocatalysis promises a cleaner and more cost-effective process with excellent selectivity in asymmetric
synthesis. Biocatalysis can be employed in the asymmetric total synthesis of groups of naturally
occurring chemical compounds, combining the flexibility of chemical routes with the high degree of
chemo and enantioselectivity displayed by enzymes. Therefore, the challenge facing the biocatalysis
community is how to extract or mine the marine ecosystem for novel biocatalysts that will fit the
industrial drug development pipeline and perform chiral conversions as required. In some cases, the
marine enzymes already possess chiral activity, as reported with the synthesis of chiral hydroxy esters
using Actinobacteria [48]. In other cases where the substrate profile of the enzyme is particularly
interesting, directed evolution and random or targeted mutation of lead biocatalysts is an option
(discussed later). Another area worth pursuing is the use of PKS enzymes and the different enzymatic
domains that make up each modules as biocatalysts which enable the synthesis of polyketides in vitro.
Hughes and colleagues reported how the terminal module and the thioesterase (TE) module of the
erythromycin PKS (EryMod6EryTE) was capable of generating triketides on a scaled-up level from
simple synthetic diketides and enzymatically generated building blocks [49]. Piasecki and co-workers
demonstrated the ability of PKS enzymes to generate chiral building blocks on a preparative scale,
going so far as to propose that “if PKS enzymes, themselves, were harnessed as biocatalysts, covered
chiral building blocks and biologically active molecules would be more readily accessed” [50].
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4. Culture Dependent and Independent Approaches to Unravel the Biocatalytic Potential of the
Marine Environment
The marine ecosystem has been described for its great potential of novel bioactive compounds
used in pharmaceutical and biotechnological industries [51–58]. Among the bioactive compounds
produced by marine microorganisms, biocatalysts have emerged as an interesting alternative to the
classic catalyst. In addition to their potential for chiral synthesis and their contribution to promoting
green chemistry synthesis [59,60], marine biocatalysts display unique physicochemical properties,
can transform spatial niche-unique substrates, and represent an untapped novel biodiversity not likely
to be matched by terrestrial niches which have been extensively explored.
One consequence of the unique physicochemical and nutrient conditions of the various marine
spatial niches is our inability to successfully cultivate the microbial diversity that exists therein. It is
well known that isolation and cultivation of novel marine microorganisms is a major bottleneck for the
discovery of novel marine bioactive compounds. Typically only from 0.001% to 1% of bacterial isolates
can be recovered and grown under laboratory conditions [61]. In recent years, different approaches
have been taken in order to improve the success rate of culturable bacteria [62], including the
efforts of the currently active EU FP7 MaCuMBA consortium (http://www.macumbaproject.eu/) [63].
However, the fact that most microorganisms exist within polymicrobial communities in their natural
environments, perhaps evolved to exploit interdependence with other microorganisms in these
complex spatial niches, hampers efforts to culture microorganisms in artificial culture media [1].
Despite the low percentage of culturable bacteria, progress made in the last decade regarding
Next Generation Sequencing (NGS) has generated a vast amount of genomic information that scientists
can exploit in order to unravel the biotechnological potential of natural environments [64]. It is
known that more than 70 bacterial phyla have no cultured representatives [1]. To explore this
massive untapped genetic information, the latest advances in “omics” technologies are currently being
used [65]. Metagenomics is one such approach, involving genomic and gene expression analysis of both
culturable and unculturable microorganisms [66]. Based on genomic technologies (genome mining
and metagenomics libraries, Figure 3) novel biocatalysts have already been described from marine
microbial sources, primarily using three approaches (summarized in Table 1). Genome-based screening
methodologies employ bioinformatic searches for specific protein domains in the genome sequences
of marine culturable bacteria. These are limited by both the culturability of the marine organism
and also the presence of an already known sequence or motif. Of course it is important to note that
while an enzyme identified in this way will almost certainly possess the same catalytic motif as the
already characterised subject upon which the search is based, the properties and substrate specificities
of these enzymes have the potential to be remarkably different. Function-based screening is generally
based on high-throughput analysis of metagenomics libraries (the culturable and unculturable biome)
for specific biocatalytic activity, more often than not using generalised substrates. An example of
this is the use of tributyrin for lipase screening. However, while this approach has the potential
to bypass potential bottlenecks such as sequence divergence by focusing on functionality, its full
potential is somewhat limited by the use of these generalised substrates. The real potential for the
screening approach will be realised when challenging substrates, that are commercially important,
are available and adapted for screens. This will make the search more challenging, but the outcome
will be more fruitful. Sequence-based screening differs from the genome based approach described
above in that it is based on the sequencing of metagenomic libraries. Similar to the genomic
approach, specific bioinformatic searches are used to identify DNA sequences/protein domains
of enzymes of interest. Alternatively, the genetic information can be extracted from the libraries using
sequence-informed degenerate primers based on the enzymes sequences present in different databases.
From a sequencing perspective, the potential biodiversity currently existing in publically available
databases (between 104 and 105 protein sequences) is markedly lower than the mathematical potential
of a fully random selection of amino acids (10201 for 200-amino acid proteins) [23]. This indicates
a significant level of coding-based constraints, whereby not all mathematically possible sequence
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diversity can or do manifest in nature. This has consequences for downstream synthetic approaches
used to optimize or improve novel biocatalysts, irrespective of their source. Mathematical models
coupled with smart molecular methodologies will enable researchers to bypass incompatible sequence
combinations, thus fast-tracking the creation of functionally viable derivatives. First, however,
we have to be able to access that genomic data, and that requires us to access both the culturable and
non-culturable organisms that encode the full breadth of sequence diversity.
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Table 1. Marine microbial biocatalysts discovered based on genome mining and
metagenomic approaches.
Marine microbial enzymes Screening method Environmental DNA source (G or M)a Reference
Ald hyde reductase Genom -bas d G-Oceanospirillum sp. MED92 [67]
Dehalogenase Genome-based G-Psychromonas ingrahamii [68]
Lipase (Lip 1) Genome-based G-Pseudoalteromonas haloplanktis [69]
Alkane hydroxylase (AlkB) Function-based M-Deep sea sediment [70]
β-Glucosidase (Bgl1A) Function-based M-Surface seawater [71]
β-Lactamase Function-based M-Cold seep sediments [72]
Chitinase Sequence-based M-Aquatic habitats [73]
Chitinase Function-based M-Coastal and estuarine waters [74]
Endo-1,4-Glucanase Function-based M-Brown algae [75]
Esterase (5 different Est) Function-based M-Brine:seawater interface [76]
Esterase (EstA and B) Function-based M-Surface seawater [77]
Esterase (EstAT1 and AT11) Function-based M-Seashore sediment [78]
Esterase/Lipase Function-based M-Deep-sea sediment [79]
Esterase (EstEH1) Function-based M-Marine sponge [80]
Esterase (EstF) Function-based M-Sea sediment [81]
Esterase (EstKT4, T7 and T9) Function-based M-Tidal flat sediment [82]
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Marine microbial enzymes Screening method Environmental DNA source (G or M)a Reference
Esterase (Est6) Function-based M-Sea sediment [83]
Esterase (EstATII) Function-based M-Red Sea brine pool [84]
Esterase (Est97) Function-based M-Intertidal zone [85]
Esterase (EstEP16) Function-based M-Deep sea sediment [86]
Esterase (Est9X) Function-based M-Surface seawater [87]
Fumarase (FumF) Sequence-based M-Sea water [88]
Glycoside hydrolase (GH-57) Sequence-based M-Hydrothermal vent [89]
Glycoside hydrolase (BglMKg) Function-based M-Sea water [90]
Hydrolase (CelM) Sequence-based M-Artic ocean [91]
Laccase (Lac15) Sequence-based M-Surface seawater [92]
Lipase (h1Lip1) Function-based M-Sea sediment [93]
Lipase (LipG) Function-based M-Tidal flat sediment [94]
Lipase (EML1) Function-based M-Deep-sea sediment [95]
Lipase (Lpc53E1) Function-based M-Marine sponge [96]
Lipase (LipA) Function-based M-Marine sponge [97]
Protease Function-based M-Sea sediment [98]
Protease Function-based M-Sea sediment [99]
a G: genomic DNA source; M: metagenomic DNA source.
4.1. Culture Dependent Approach
4.1.1. Marine Bacteria as an Untapped Source of Novel Biocatalysts
The advent of molecular phylogenetic analysis tools such as 16S rDNA and ISPro sequencing has
led to the realisation that a significant proportion of microbial species have never been cultured. It is
estimated that somewhere between 105 and 107 distinct prokaryotic and lower eukaryotic species exist,
with organisms from extreme environments proving the most refractive to conventional culturing
techniques [100,101]. In recent years, relevant improvements have been performed in order to increase
the number of culturable bacteria based on classical approaches, trying to mimic the natural conditions
of the marine environment [102–104].
The marine environment harbors an enormous bacterial diversity, with microbes being described
as the primary biomass producers, playing a key role in the global cycling of elements within
this ecosystem [105]. This role is underpinned by the large repertoire of biocatalytic activities
encoded within marine metagenomes, facilitating the biotransformation and cycling of marine-specific
substrates that enable their colonisation of this niche. As such, marine microbes are continually
exposed to extreme conditions found in the different sub-habitats, displaying a high biochemical
diversity reflecting the presence of unique substrates. Marine microbes can exist as planktonic free
cells or as sessile biofilms within polymicrobial communities, the latter promoting persistence in
harsh ecological niches. Bacterial colonies are often compared to simplistic biofilms, with Kolter
and Greenberg describing them as ‘air exposed biofilms’ [106]. However, other studies have
shown that bacterial colonies more closely resemble planktonic cells “stranded” on a surface,
so therefore the line between both lifestyles is somewhat blurred in need of further clarification [107].
Marine microbes can also live in symbiosis with marine invertebrates, adding another layer of
complexity to their interactome. Marine sponges have been reported to produce an array of
diverse bioactive compounds, many of which we now know to be produced by the symbiotic
bacteria [108]. The marine sponges themselves produce metabolic waste and different secondary
metabolites including halogenated organic compounds [109,110]. These compounds can potentially
play an important role as unique substrates that support the evolution of novel biocatalysts such as
halogenases and dehalogenases [111,112]. The novelty attributed to these activities has been varied and
ranges from sequence level, physicochemical, substrate specificity amongst other properties. While
sequence novelty is of interest at the community level, there is a strong likelihood that not all of the
sequence biodiversity observed in marine biocatalysts will manifest at the functional level. Glycosyl
Hydrolases for example are classified using the CaZy system, based on sequence motifs rather than the
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classical enzyme classification. Novel GH sequences classified in this way will not necessarily perform
new biotransformations or possess improved physicochemical properties. Therefore, functional
characterization of enzymes possessing novel sequences needs to be fast-tracked to inform future
studies. Notwithstanding this, as the number of biocatalysts harvested from the marine microbiome
continues to expand, the possibility for new and improved functionalities becomes more of a reality.
The discovery of novel biocatalysts from culturable marine bacteria has been achieved through
distinct methodologies and approaches. One of the most commonly utilised approaches from a culture
dependent point of view is the detection of novel biocatalysts based on functional screening followed
by PCR typing for taxonomic profiling. Once identified, individual genes encoding the required
activity can be cloned, expressed in a suitable host and the purified protein characterized biochemically.
Using this approach, several enzymes from marine microbes such as dehydrogenases, lyases, xylanases,
chitinases, epoxide hydrolases, and esterases, between others, have been detected [113–119]. One of
these examples is the case of cold-adapted isocitrate lyase (ICL) from the psychrophilic bacterium,
Colwellia psychrerythraea [118]. An alpha-amylase from Nocardiopsis sp. (deep sea sediment of Prydz
Bay) and a carboxymethyl cellulose from Marinimicrobium sp. LS-A18 were identified using both
whole cell and crude extracts [120,121]. In the specific case of α-amylase the activity was determined
by detecting the amount of reducing sugars liberated followed by thin layer chromatography (TLC)
analysis to detect the hydrolysis products of starch [120]. Adding subsequent additional steps of protein
purification, enzymes such as dehalogenase and alkaline lipase were detected [112,122]. The authors
also demonstrated the presence of two distinct 2-haloacid dehalogenase activities detected in the cell
crude extract after ammonium sulfate fractionation in the bacterial strain Pseudomonas stutzeri DEH130
isolated from the marine sponge Hymeniacidon perlevis [112]. Dehalogenase I was mainly active toward
D-2-chloropropionate (D-2-CPA), whereas dehalogenase II exhibited at least 10 times more activity
against L-2-chloropropionate-L-2-CPA. This suggested that P. stutzeri DEH130 could contain two
stereo-specific dehalogenases. Bacillus smithii BTMS 11 strain isolated from marine sediment, was the
source of a novel alkaline lipase, extracted by ammonium sulfate precipitation and ion exchange
chromatography [122]. Enzyme characterization by SDS-PAGE and zymogram analysis confirmed the
protein band which showed the lipase activity. Other approaches have been based on the construction
of genomic libraries of bacterial candidates for a pre-determined enzymatic activity, from which a low
temperature catalytic cellulase and two different pectate lyases isolated from the Antarctic bacterium
Pseudoalteromonas haloplanktis have been identified [123,124]. Among the 10,000 clones screened for
the cellulolytic activity using L-agar plates with carboxymethylcellulose and Trypan blue, only one
positive clone was isolated [123]. In the case of pectate lyases, approximately 15,000 clones were
screened in LB-agar plates containing 0.1% (w/v) citrus pectin and five colonies with pectinolytic
activity were observed. The DNA was sequenced and two open reading frames were found, both
ORFs exhibiting sequence identity to pectate lyases from Erwinia chrysanthemi [124].
Nowadays, more modern approaches due to development of the NGS technologies are considered.
Genome mining could emerge as an alternative to the culture dependent approaches described
above. Genome mining offers the possibility of discovering potentially novel biocatalysts using
bioinformatic tools. Protein domain analysis of genome sequences from culturable organisms, could
reveal potential novel biocatalysts, which cannot be detected by the previous experimental procedures
mentioned. However, this approach is limited to near neighbor proteins, limiting the novelty somewhat
to previously identified domains. This is due to the fact that the sequence based searches are based
on similarity algorithms that score based on sequence identity. The more novel the sequence, the less
likely a “hit” will present itself during the analysis stage.
4.1.2. Genome Mining: An Under Exploited Source of Biocatalyst Discovery
The expansion of microbial genome sequencing over the last 20 years [125], through the increase
of the speed of NGS and the decrease in cost of genome sequencing, has provided the basic tools
for the in silico discovery of genes and gene clusters related to the production of novel marine
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natural products and biocatalysts [64]. However, the rapid increase of marine metagenomic DNA
information in the database [126] has largely supplanted the directed genome approach. Recent
efforts to decipher the extent of the oceans microbial biodiversity and the novelty of marine bioactives
with biotechnological potential include the global Ocean Sampling Day; a simultaneous sampling
campaign of the world’s oceans performed under the umbrella of the Micro B3 Project from the
EU (https://www.microb3.eu/osd) [127]. To date, there are only few reports that describe the use
of genome sequence of marine bacterial strains to identify and subsequent characterize potential
biocatalysts [67–69].
In 2008, de Pascale and co-workers describe the presence of a novel cold-active lipase (called Lip1)
from the Antarctic bacterium Pseudoalteromonas haloplanktis TAC125. These authors used the previously
published genome sequence of this bacteria [128] to carry out a computational search and identification
of lipase-encoding sequences. Based on conserved motif analysis and multi alignments of seventeen
homologous genes, Lip1 and other related genes constituted a novel lipase family, typical of
psychrophilic marine γ-proteobacteria. Another study carried out by Novak and co-authors (2013)
in the psychrophilic bacteria Psychromonas ingrahamii DSM 17664 described for the first time the
biochemical characterization of an L-haloacid dehalogenase. Based on the available genome sequence
of this bacterial strain [129], the authors used specific primers designed on the sequence of the
pinHAD gene to amplify and clone this gene into the pET-28a protein expression vector. This enzyme
was over-expressed, purified using nickel affinity chromatography columns, and biochemically
characterized. The activity was measured using a colorimetric assay, based on the presence of phenol
red at pH 8.2, and using as the substrate monochloroacetic acid. Substrate specificity analysis showed
that this enzyme presented highest activity towards substrates with short carbon chains (ďC3), and that
it was stable in different organic solvents at different concentrations. Despite the fact that the enzyme
was isolated from a psychrophilic bacterium, it showed an optimal activity temperature of 45 ˝C.
Essentially, a similar approach has been used by Li and co-workers (2013), to determine
bioinformatically and subsequently, amplify and clone a NADPH-dependent aldehyde reductase
in Oceanospirillum sp. MED92, based on its previous genome sequence report [130]. This enzyme
called QsAR, showed activity against a wide range of aliphatic and aromatic aldehydes, but displayed
no activity against ketones, suggesting that this enzyme catalyzed the chemoselective reduction of
aldehydes in the presence of ketones.
The large number of marine bacterial genome sequences coming on stream in the publically
available databases suggests that the genome mining approach will provide a lucrative window for
the identification of novel biocatalysts, notwithstanding the near-neighbor constraints described above
that hamper sequence homology based approaches.
4.2. Culture Independent Approach: Metagenomic for Biocatalyst Discovery
The culturable bottleneck has several aspects. It is generally accepted based on genomic data that
the majority of marine prokaryotes have not yet been cultivated. Of even more concern is the fact that,
of those organisms we can cultivate, the majority do not come from extreme environments, niches
from where valuable activities are likely to be extracted [131]. Metagenomics provides a valuable
tool to attain the genetic information of the vast majority of the microbial community in a sample,
underpinning a major advance in understanding of the existing genetic diversity, population structure,
and ecological roles of microorganisms in the marine environment. According to Handelsman, the term
metagenome can be defined as “the genomes of the total microbiota found in nature”, referring to the
sequence data directly sampled from the environment [132]. Thus, metagenomics provides culture
independent access to valuable genetic resources of the uncultured microbes [77]. With the upsurge in
the development of more efficient and powerful tools to explore the huge genetic potential that comes
from natural environmental sources, the modern biotechnology field is well placed to deliver on the
early promise of novel bioactivities [66,78,132–138].
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Metagenomics-based approaches have focused on both gene clusters and singular genes encoding
enzymes, delivering on the enhanced discovery of biocatalysts for synthesis and production of
secondary metabolites and other bioactive compounds [139]. Barone and colleagues (2014) categorized
the three distinct environments for which metagenomics-based biodiscovery can be applied: highly
diverse environments like soil and seawater, naturally or artificially enriched environments, and
finally, extreme environments [1]. The breadth and diversity of the marine ecosystem encompasses
elements of all three categories, providing unique habitats for the organisms living therein [140].
Marine microbes comprise a wide variety of communities that are well adapted to living in this
challenging ecosystem, either surviving as free-living organisms or in association with other organisms
such as marine animals [141]. Of course, harnessing such diversity is not without its own bottlenecks,
even at the genetic level. The hit rate in metagenomics studies is both determined and limited by
several factors: the chassis or host organism, the size and complexity of the target gene or gene cluster,
its abundance within the sample, the screening method, and the fidelity and downstream functionality
of the protein in the heterologous host. In this regard, the development of compatible broad host
range shuttle vectors and suitable chassis organisms for expression and production of heterologous
proteins remains a significant challenge. Furthermore, the reliance on classical screens has limited
the extraction of novel activities even when these challenges are overcome in a particular sample.
Therefore, an integrated and highly focused multidisciplinary effort will be required at all levels of the
metagenomics pipeline in order to pursue the ultimate goal of harnessing the complete biodiverse
potential of the marine and other ecosystems.
4.2.1. Metagenomic Screening Strategies
As a rule of thumb, in all metagenomic screening strategies, once environmental DNA has been
isolated, the first step is the construction of a DNA metagenomic library in a suitable host cell [142,143].
In itself, DNA isolation and packaging has proven a significant limitation to biodiscovery from
rare-producing organisms due in part to low abundance, prohibitively high or low %GC content, as
well as incompatibility with the cloning and vector systems employed. In some cases enrichment
prior to DNA isolation can improve the hit rate, as in the case of symbiotic bacteria associated with
marine sponges or other invertebrates [144–147]. Once the DNA has been captured, the success of the
subsequent metagenomic screening strategies, and consequently the discovery of novel biocatalyst
candidates isolated from unculturable marine sources, is directly determined by the degree to which
gene expression and proper protein folding is achieved in the heterologous cell host [148]. Once
the metagenomic library has been constructed, the metagenomic screening approaches comprises
principally of two complementary methodologies that can be based on either function (activity) or
sequence [149]. Function based screening, while direct and relatively informative, is hampered by the
biased and often unsuccessful expression of foreign DNA in the heterologous host of choice, classically
restricted to Escherichia coli (E. coli). On the other hand, while sequence based screening has benefited
from the explosion in metagenomic sequencing projects, and the availability of sequence data for PCR
or hybridization design, this approach is largely restricted to near neighbour sequences and may not
deliver on the rare biocatalytic activities being sought from the marine environment. Nonetheless,
both approaches are central components in the bioprospecting toolkit and advances in both approaches
have greatly improved their utility.
Metagenomic Functional Screening
Metagenomic functional screening is based on the direct screening of potential function, before
any analysis of nucleotide, ribonucleotide or protein sequences [150]. Thus, in order to detect efficiently
the potential candidates (clones harbouring biosynthetic genes of interest and which are able to exhibit
different modified phenotypes) several functional screens can be implemented. In terms of detection,
the majority of these screens are a direct method where products of individual metagenomic clones
can be detected either visually or spectrophotometrically [141]. Essentially, three classes of screens
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are employed, with the design and implementation specific to the chosen target activity. Enzyme
activities are generally screened on bioassay Q-tray plates on agar supplemented with substrate for
which conversion to product results in either a colorimetric change, a halo or zone of clearance, or
alternatively a growth no growth phenotype. All three are easily scorable and the validation rate from
these hits can be quite high. In liquid based screens, cells or cell lysates are used in multi-well (typically
96-well or 384-well) plates and the conversion of substrate to product can again be measured by growth
no growth, or alternatively a spectrophotometrically measurable change in absorbance. Finally, using
molecular tools and an increasing knowledge of the regulatory systems underpinning biocatalysis
in living organisms, reporter fusions can be developed for use as “gene traps”, where conversion of
substrate to product causes a regulatory protein to activate a fused promoter resulting in fluorescence,
X-gal hydrolysis, or antibiotic resistance. The selection of a particular screening methodology can
be enzyme specific, and some screens have been used widely within the biodiscovery community.
There are many examples in the literature, extendable to a wide range of enzymatic activities, where
function-based screening methods represent a valuable option, which have previously been employed
successfully (see Table 1).
Lipases and esterases plays a prominent role as biocatalysts, being widely employed in many
diverse fields such as textile, food, laundry, paper and pulp industries, biodiesel production and in the
synthesis of fine chemicals [1]. In 2008, Chu and co-workers reported the identification of two novel
esterases isolated from a marine metagenomic library derived from South China Sea [77]. In this study,
positive candidate clones with lipolytic activity were detected by the formation of a clear halo around
the colony growth after 2 days at 37 ˝C on LB agar plates supplemented with 1% (v/v) tributyrin
and 1% gumarabic as substrates. Similarly, other authors identified the Red Sea Atlantis II esterase
(EstATII) by means the same functional screening (after 3 days incubation, the appearance of a clear
halo around transformant was indicative of a positive candidate with lipolytic activity), before further
sequencing and identification of lipolytic encoding genes [84]. Similarly, several other independent
studies on different metagenomic libraries from brine, the seawater interface of the Urania hypersaline
basin, the Arctic sediment metagenome, a deep-sea sediment metagenome, and also from the marine
sponge Haliclona simulans, described lipase and esterase activities. [76,78,95,96]. In all these cases,
the different novel activities identified (five different esterases, two esterases with potential application,
one cold-active lipase and one halo tolerant lipase) were identified after plating on a selective tributyrin
or tricaprylin medium, according to their capacity to form clear halos.
Other examples of efficient screening methodologies relate to the identification of glycosyl
hydrolase activities, such as that described by Wierzbicka-Wos´ and co-worker (2013), where a novel
cold-active glycoside hydrolase (BglMKg) was identified [90]. In this case the positive β-galactosidase
candidates were selected by their capacity to hydrolyse X-gal, and consequently turned to dark
blue. In this work, the authors also examined the enzymatic specificity of BglMKg towards different
chromogenic substrates. A similar approach has been used by Lee and colleagues (2007) and
Prabavathi and colleagues (2012), where the isolation of two novel protease activities was reported
from marine metagenomic libraries derived from sea sediment [98,99]. In both cases, the screening of
the metagenomic library for proteolytic activity was performed on SMA (skimmed milk agar: LB agar
+ 10% (w/v) milk solution with to a final concentration of 1% (w/v)) and the positive proteolytic clones
were selected based on the formation of halo zone of clearance around the colony. As discussed earlier,
the list of screening methodologies available for the isolation of biocatalysts from metagenomic libraries
is well established and does provide a considerable hit-rate from marine and other source samples.
However, many of the activities that have been isolated using these screens are not novel, nor does the
screen assess or select for novelty by design. Therefore, the challenge remains to begin to design smart
screens based on industrially relevant substrates to look for characteristics such as substrate specificity,
selectivity, chirality and enzyme stability, the very features we are seeking in the “ideal biocatalyst”.
That is not to say that generic substrates do not have a role in the functional screening approach.
There is some evidence to suggest that enzyme promiscuity may provide access to novel activities,
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albeit not in a selective manner. Low efficiency but relatively unrelated enzymes may be detected in
sensitive screening assays, as seen with the isolation of an esterase/β-lactamase dual activity from a
leachate metagenomic library [151]. The key to this is recognizing and interpreting the outputs from
the comprehensive primary screen, and selecting the appropriate downstream biochemical tests to
validate the activity.
Metagenomic Sequence-Based Screening
The Metagenomic PCR-based approach (also called Metagenomic DNA Sequence-based
Screening) is another alternative methodology, primarily based on the analysis of nucleotide,
ribonucleotide or protein sequence. Typically, a set of degenerate primers are designed based on
available consensus sequence data for the target locus are used. Alternatively, hybridization with
probes can be used to extract the sought after genetic information. Either way, screening based on the
detection of DNA and has the advantage of identifying novel activities without the need for expression
in a heterologous host [142]. Of course, functional expression will still be required and present its own
challenges. However, these limitations are avoided at the screening stage, reducing the rate of false
negatives owing to inefficient heterologous expression. Depending on the depth of sequencing, analysis
of metagenomic DNA environmental samples can provide a fundamental understanding of the ecology
and biogeochemistry of uncultured marine microbes. From 2009 to 2015 the number of metagenome
sequencing projects has increased from 199 to 607, while there are currently 22,455 non-metagenomic
studies listed on the GOLD site (http://www.genomesonline.org) [152]. The enormous quantity of
sequencing data presents an opportunity to explore the novel genes of interest that undoubtedly will
exist therein. Nevertheless, there are limitations and this approach, not least the degree of novelty
accessible through this approach. The fact that the method relies on known sequences deposited in
databanks, it is restricted to the detection of homologous enzymes. To date, the amino acid identities of
newly discovered sequences compared to those already present in the databases has been above 50%,
and typically has been in the range of 70%–90%, with the possible exception of members of the lipase
class of enzyme [153]. Therefore, extending below that range may require alternative approaches such
as functional screening, or improved annotation and predictive software to identify domain structures.
Sequence analysis of environmental DNA from the Sargasso Sea Whole Genome Sequence (WGS)
data performed by Cottrell and co-workers in 2005, enabled the search for novel hydrolases (CelM)
used by Cytophaga-like bacteria, revealing the cellulase gene celM [91]. In this study, PCR primers
were designed for the most abundant type of endogluconase identified in the WGS data set, and were
used to screen a fosmid library constructed with prokaryotic DNA derived from the western Arctic
Ocean. Jiang and co-workers (2010) constructed a plasmid metagenomic library from marine water
samples derived from the Arctic Ocean [88], from which they identified the novel fumarase gene
fumF. Fumarase activities have been extensively applied for the industrial conversion from fumarate
to L-malate, and are another example of the breadth of profitable biocatalysts that can be mined
from environmental samples. Wang and co-workers (2011) discovered a novel glycoside hydrolase
activity (GH-57) from a metagenomic fosmid library derived from the Mothra hydrothermal vent and
randomly pyrosequenced [89]. Using the fosmid library as a template, and based on DNA sequence
analysis of the gh-57 fragment, degenerate primers were designed to successfully amplify the gh-57
gene fragment, which could subsequently be expressed heterologously. In another study, Fang and
co-authors (2011) used the sequencing strategy to discover new bacterial laccase genes of 1.32 kb
isolated from microbial metagenomic libraries derived from the South China Sea [92]. Their screen
was based on the conserved region of laccase encoded copper-bing sites. Laccases, as a biocatalyst,
have received attention for relevant applications in both environmental and industrial biotechnology.
In spite of the obvious drawbacks in sequence and homology based searches, novel lipases have been
isolated with greater frequency than other classes of enzymes from metagenomic samples. Indeed,
new families of lipase have been described based on accumulating sequences and this extends the
capacity to mine with greater depth for similarly novel sequences from marine and other niches [154].
Mar. Drugs 2016, 14, 62 15 of 29
As the extent of annotated diversity increases, so does our capacity to recognize and identify
sequences with greater novelty through homology based searches. However, crucially, whether or not
this translates into functional novelty, or indeed retains the annotated activity needs to be established
post-screening. The challenge to the biodiscovery community is to accelerate the translation of sequence
novelty into functional novelty. While it is clear that current screening approaches have led to the
isolation and characterization of novel sequences, most notably with the lipase class, this has not as yet
manifested as novel functionality. Assay development and more sophisticated annotation programmes
can assist in achieving this goal. Alternatively, the novel sequences obtained from metagenomic
samples can be used as platforms for a series of downstream molecular manipulations, collectively
described as directed evolution.
5. Biocatalytic Improvement by Directed Evolution
As mentioned in the previous section, the rapid increase in NGS technologies, has provided
an immense amount of novel biocatalyst sequences from different sources [155]. Despite the fact
that biocatalysts potentially exhibit significant advantages when compared with chemical catalysts,
in many cases natural enzymes are not functionally optimized for practical application in the industrial
sector. In this respect, the directed evolution of enzymes has been described as a powerful tool for
improving the critical traits of biocatalysts [156–159].
5.1. Directed Evolution of Enzymes
The marine environment could play an important role in the discovery of novel enzymes mainly
due to the presence of novel substrates that cannot be found in other environments. Although a diverse
range of marine enzymes have been discovered in the last decade, to date, there are a limited number
of reports where directed evolution methods have been applied to improve the activity of marine
derived primary enzymes [160–166]. Of course, questions as to the utility of directed evolution versus
the search for rare and naturally adapted enzymes needs to be considered. As directed evolution
technologies adapt from random modification to targeted structure based approaches, the stage at
which molecular systems can provide the entire spectrum of possible sequences is approaching. At that
point, the utility of sequence based searches based on known motifs may become redundant. However,
for now, the tandem use of both approaches is most likely to yield the maximum success. In this section,
we describe the implementation of directed evolution approaches that have been successfully applied
to “improve” marine enzymes, and discuss how this can help unravel the huge potential promised
by the diversity of the marine ecosystem. The sequence-diversity of marine biocatalysts, and their
uniqueness relative to bioactivities from other environmental spatial niches, presents a new building
block or scaffold upon which directed evolution approaches can be applied. This can potentially
increase the possibility of creating biocatalysts with new and superior properties relative to those
created using the more conserved scaffold sequences that have already been used.
The common element shared by directed evolution approaches, and also one of the major
bottlenecks to this technology, is the generation of a diverse mutant library. Different approaches
have been developed, using different mutagenesis methods to generate smaller and higher quality
libraries [156,167]. Basically, three main strategies are followed for the generation of a sequence library:
(1) random mutagenesis, (2) site-directed saturation mutagenesis, and (3) genetic recombination.
A general overview of the basic workflow on directed evolution of enzymes is represented in Figure 4.
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5.1.1. Random Mutagenesis
The random mutagenesis approach is considered the classical mutagenesis technology for
generating libraries, and is still broadly used. This approach only requires limited knowledge of
the parent protein, and large libraries with low mutation rates and uneven mutational spectra are
often obtained [167]. Different types of random mutagenesis have been described such as chemical
mutagenesis, mutator strains and error-prone PCR (epPCR).
Chemical mutagenesis is the most traditional way for generation of mutant clones, and different
chemical agents can be used for this purpose. Ethyl methanesulfonate (EMS) is one of the most
common chemical agents utilized but also another compounds such as nitrous acid and bisulfite have
been successfully used [168,169]. Recently, EMS along with other chemical and physical mutagens
(nitrous acid, acrylamide, ethidium bromide and ultraviolet radiation) was successfully applied to
improve an α-amylase activity from Brevibacillus borostelensis R1 isolated from marine water [163].
Although the increase in the fold yield of α-amylase activity was modest, reaching 1.41 as a maximum,
at least nine mutants obtained by different mutagens were identified, providing new platforms for
the next cycle of enhancement. Alternatively, it is well known that DNA polymerase during DNA
replication can introduce mutations at different rates depending on the organism. Using mutator
strains that contain non activated proofreading and repair enzymes such as mutS, mutT and mutD,
DNA polymerase can increase the mutation rate [170,171]. The main problem associated with this
approach is that the mutations not only affect the target gene selected for the library construction,
but also introduce mutations that can be deleterious in the host genome. The drawbacks inherent
in both strategies has led to the development of an in vitro strategy based on a PCR. Error-prone
PCR (epPCR) described for the first time by Leung et al. 1989, uses a Taq DNA polymerase with
no proofreading activity that is modulated by the composition of the reaction buffer [172]. In this
context, the low fidelity of DNA polymerase generates random mutations during the PCR amplification
of the selected gene. Thus, during each PCR cycle, DNA polymerase can increase the number of
mutations per clone. A novel cold-active esterase from Serratia sp. isolated from marine environment,
that showed a remarkable catalytic activity at low temperature, showed increased thermostability
following epPCR cycling [166]. A random library of 8000 mutant clones was analysed based on
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retention of esterase activity after incubation at high temperature. One clone that showed higher
thermostability was found and designated as 1-D5. Gene sequencing revealed three alterations in
the amino acid sequence. Following this same approach, Zhou and colleagues (2015), increased
the thermostability of an α-glucosidase from Thermus thermophiles TC11[164]. After the screening of
2,700 ep-PCR library clones, one mutant that carried one amino acid substitution (Q10Y) showed
increased thermostability. Altough the residual activity was 20% higher in the mutant than in the wild
type, the specific hydrolytic activity towards pNP-α-D-glucopyranoside (pNPG), was lost with the
increase in thermostability. Furthermore, Chen and co-workers [161], used epPCR on the thermophilic
cellulose cel5A gene from Thermotoga maritima, generating two mutants that had increased activity
on pretreated switchgrass, reducing the recalcitrance of lignocellulosic biomass. A common thread
to these approaches is the need for large libraries of clones, with low hit rates from the mutants.
Furthermore, as the libraries generated by the random mutagenesis approach are larger and can be of
limited quality, other focused strategies have been designed.
5.1.2. Site-Directed Saturation Mutagenesis
Site-directed saturation mutagenesis (SSM) is a more focused approach, and can be used to create
“smarter” libraries [157,173]. To date, many proteins are really well characterized structurally and the
specific residues to bind different substrates or those involved in catalysis are well known. Although
SSM can be applied to generate mutations in every position in a gene, previous structural data or
homology based sequences are used to select specific residues [174]. In this approach synthetic DNA
primers that carry the desired mutations are used in a PCR to test all 20 amino acids in a target
position. This can be achieved using the trinucleotide NNN in the target amino acid. A small variation
of this strategy is performed using the codon NNK, instead of NNN, decreasing the number of
variants, and thus, reducing the screening efforts in the libraries generated [175]. Enzyme promiscuity
has been considered as an important prerequisite for fast divergent evolution of biocatalysts.
In this regard, the phosphotriesterase-like lactonase (PLL) enzymes exhibit classical lactonase and
promiscuous phosphotriesterase activities. Theses enzymes are important as bioremediation tools
for the degradation of neurotoxic organophosphates, being an attractive target for directed evolution
techniques. Zhang and co-workers (2012) utilized a thermostable PLL from Geobacillus kaustophilus
HTA426, isolated from marine sediments, as a parental gene [160]. Using a combination of SSM and
epPCR, several active mutant variants were obtained. The most active mutant variant, 26A8C, that had
undergone eight amino acid substitutions, showed a 232-fold increase activity against the OP pesticide
ethyl-paraxon, and 737-fold decrease in lactonase activity. High hydrolytic activities were also shown
for a wide range of OP pesticides. Zhang and co-workers(2015), utilized the same enzyme from the
same organism to investigate the promiscuity of the binding site [165]. Based on amino acid sequence
alignments with a phosphotriesterase enzyme (PTE) using also the crystal structure of the PLL from
G. kaustophilus HTA426, the authors observed how the position Tyr99 (Y99) in the binding site of this
enzyme, could be involved in the substrate discrimination. Using an SSM approach, they found one
mutant with the change Y99L, that showed an 11-fold increase phosphotriesterase activity, and 15-fold
decrease lactonase activity. A structural analysis of this mutant position revealed an outward shift of the
adjacent loop 7 that was proposed to increase the flexibility of the active site, suggesting that the active
site conformation loop regulates the promiscuous activity. Reetz and Carballeira (2007), proposed the
Iterative Saturation Mutagenesis (ISM) where the authors combined in an iterative manner, the SSM
approach described previously [176]. This strategy has been also used to successfully improve different
properties such as thermostability, substrate or enantioselectivity [177]. For example, ISM has been
successfully used to enhance the enantioselectivity of an esterase from Bacillus stearothermophilus [178],
and to improve the activity of a Baeyer–Villiger monooxygenase [179]. Another approach reported by
Reetz and co-workers (2005) called combinatorial active-site saturation test (CAST), is based on the fact
that different amino acids positions can be simultaneously mutated, and this can affect the synergistic
conformational and electrostatic activity of the enzyme [180]. Sandström and co-workers (2012),
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developed a novel method for radically reshaping the active site of a lipase A from Candida antarctica
based on CAST library technology improving the activity and enantioselectivity toward difficult
substrates [181].
5.1.3. Genetic Recombination
DNA shuffling as a directed evolution method was described for the first time by Stemmer
(1994) [182]. It is an in vitro DNA recombination strategy in which homologous genes (parent genes)
from different species are randomly fragmented by DNase I and fragments of desired size are randomly
reassembled using a PCR reaction without added primers. After this reassembly, PCR amplification
with primers is used to generate full length chimeras suitable for cloning into an expression vector.
This mutagenesis technique was successfully applied to create an E. coli aminotransferase that accepted
β-branched substrates, which were poorly accepted by the wild type enzyme [183]. In another
study [162], the authors addressed the bioremediation problem of herbicides in the agricultural sector.
Glyphosate is a broad spectrum herbicide widely used in agriculture, and the glycine oxidase, has been
described to catalyse the C–N bond in glyphosate. epPCR combined with DNA shuffling improved
the activity of a glycine oxidase from a marine strain of Bacillus cereus. The most active mutant variant
obtained in this study showed a 160-fold increase in substrate affinity and a 326-fold enhancement
in the catalytic activity towards glyphosate. Through structure modelling and molecular docking,
the authors suggested that the mutant position 51 (Arg51) close to the active site could play a role in
the stabilization of the glyphosate binding.
This method accelerated greatly the evolution rate of these genes, but, only a small number of
variants can be obtained when the parent genes present low sequence homology regions. In this respect,
a related method reported by Coco and co-workers (2001) improved the recombination sequence
and offered a more comprehensive exploitation of sequence space. This method called random
chimeragenesis on transient templates (RACHITT) uses a similar approach to DNase fragmentation
but utilizes a different way of DNA reassembly [184]. Although the new stream in directed evolution
is focused on the use of sophisticated and more precise methods to generate smart libraries (small and
high quality), these approaches require a deep knowledge in molecular structures, homology modelling
and phylogenetic information to decipher which specific mutations are the most important to increase
the activity of a determined enzyme. Random mutagenesis can overcome this requirement when these
data are not available, and has the added advantage of creating mutations independent of what would
be considered logical based on existing protein sequence information, and completely independent
of those present through the normal evolutionary process. Fortunately, all the different strategies
(random, SSM and genetic recombination) can be applied together, with the potential to maximize the
likelihood of success [185].
6. Synthetic Biology
Despite the undoubted potential of metagenomics based biodiscovery for the isolation of novel
biocatalysts, several issues need to be resolved before we can begin to realize the true potential of these
technologies and harness the true extent of the natural biodiversity that exists in our environmental
samples. These include (i) the bias encountered in using a heterologous host, typically E. coli for
expression of metagenomic DNA, (ii) the ability of the vector system to express the target sequence,
(iii) the capacity for the host to properly fold and potentially secrete the active protein, and (iv) the
effectiveness and sensitivity of the screening strategy to detect the biotransformation when it occurs.
A series of technological advances under the umbrella term of synthetic biology are under development
to address each of these issues. Synthetic biology in its own right has a projected global market value
of US$10 Bn for 2016 and is intrinsically linked to the directed improvement of industrially relevant
bioactivities [186]. Comprising both enabling and core technologies, the area of synthetic biology
will continue to grow and lead the genomics-based optimization of bioactive compounds for the
foreseeable future.
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It is perhaps unsurprising that the extent of natural biodiversity encoded in the earth’s microbiome
has not yet manifested in screening or targeted biodiscovery programmes, given the focus on a
limited spectrum of heterologous hosts or chassis organisms. For the most part, E. coli has been the
organism of choice for synthetic biology, with Streptomyces, Pseudomonas, and Rhizobia being explored
as alternatives. In spite of the availability of engineered E. coli host strains for optimized production
of foreign DNA, the current limitations are borne out by screening of the same cosmid libraries in
different hosts [187,188]. Therefore, performing the metagenomics based screening in these alternative
hosts will almost certainly expand the range of expressed and detectable activities. This brings with it
its own challenges with these alternative hosts being significantly less well adapted for heterologous
expression than E. coli which has undergone decades of development and optimization for this purpose.
However, potential chassis organisms such as Streptomyces and Pseudomonas do have the advantage
of encoding vast repertoires of bioactive enzymes and secondary metabolites, thus possessing the
machinery and metabolic systems to effectively express these activities. Increased understanding from
molecular studies of the stress adapted phenotypes exhibited by these species will also underpin their
development and optimization as chassis for metagenomics based expression.
Similarly, the design and integration of broad host and host-tailored vector systems for expression
of heterologous DNA is a major challenge that has seen incremental advances in recent years. Owing
to the fact that most biocatalysts are encoded as single genes, small insert expression libraries are
particularly suitable for mining these activities from metagenomic samples, with the caveat that
larger libraries are required for coverage. An additional advantage to this approach is the fact that
genes are more likely to fall under the control of the strong plasmid promoter ensuring expression
of the transcript. While important in their own right, it is the integration of both chassis and vector
development into tailored natural product factories that will bring the most valuable advances in the
area of biocatalytics and bioprospecting in general.
A key aspect of synthetic biology is the reprogramming and rewiring of regulatory systems
in chassis organisms. Genomics based discovery of biocatalytic enzymes has highlighted the
co-occurrence of genes encoding transcriptional regulatory proteins, unsurprising given that many
of these activities are part of the core metabolic functionality of the microbial cell. The fact that
these activities are programmable through either activation or repression lends itself to the artificial
manipulation of transcriptional, translational, and post-translational regulatory systems in the
optimal chassis organism. A key regulator of biocatalysis in microbial organisms is the LysR-Type
Transcriptional Regulator (LTTR) family. We have previously characterized LTTR evolution among the
Pseudomonadaceae, identifying several clades of co-evolved homologues [189]. Other transcriptional
regulator families also contribute to the biocatalytic regulatory framework in the cell and understanding
their role will facilitate improved chassis design. Additional synthetic biology approaches have been
to engineer the ribosome of the chassis organism, engineer factors related to translational machinery in
the host, provide plasmid encoded sigma factors and tRNAs that recognize rare codons, or alternatively
to synthetically design codon-adapted genes for expression in the chosen heterologous host [190].
In spite of the developments in this area in recent years, several aspects have been identified as
critical knowledge gaps in methods and technology (genome-scale engineering tools, DNA synthesis
and assembly, analytical tools), biological platforms (biological design principles, genetically tractable
organisms/chassis, minimal cell and in vitro systems) and computational tools and bioinformatics
(information standards, databases) [186]. Further challenges are presented on an ongoing basis by
changes in regulatory frameworks across different areas of governance for what is a global technology
operating within a global biodiscovery sampling site. New directives such as the Nagoya protocol
(https://www.cbd.int/abs/) [191] have significant implications for the use and manipulation of
genomic data that need to be addressed within the framework of current and future biodiscovery
programmes. Essentially, the Nagoya protocol governs utilisation of genetic resources for benefit,
defined as “research and development on the genetic and/or biochemical composition of genetic
resources, including through the application of biotechnology” making it subject to benefit sharing
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with the sovereignty in which it is discovered. Researchers globally will need to conform to this
and other new directives in planning biodiscovery programmes and in developing the outputs for
commercial benefit.
7. Conclusions: The Future of the Biocatalysis Pipeline
The case for pursuing marine biocatalysts for incorporation into industrial processes is well
established, and the diversity of applications continues to grow. Already there is evidence that the
unique geo- and physicochemical properties of the marine ecosystem can provide the evolutionary
pressure to select for enzymes with enhanced stress tolerance, activity towards difficult substrates, and
improved compatibility with existing industrial processes, overcoming the limitations of early lead
catalysts. Therefore, the challenge now is to maximize our ability to extract the key activities that (a)
can drive the next generation of industrial processes such as the biopharmaceutical drug synthesis
pipeline and (b) open new opportunities based on new biotransformations made possible by the
discovery of novel biocatalysts from organisms that to date have proven difficult to capture. This will
require integrated and parallel developments in all aspects of the biodiscovery toolkit, from sampling
and DNA isolation through to screening and improvement.
From a sequencing perspective, this process has already began with the availability of sequence
data encoding enzymes with lower levels of sequence identity than previously seen. This has
been driven largely by the isolation and sequencing of metagenomic samples from more diverse
environments. This move deeper into “sequence space” is predicted to drive the next phase of
sequence-based discovery, taking advantage of the explosion in sequencing projects and improvements
in standardized annotation systems. Indeed, some have gone so far as to suggest sequencing of the
entire prokaryotic metagenome [23], although the downstream analysis may still prove somewhat of a
bottleneck to achieving this.
What is clear is that parallel developments in combinations of the approaches described here will
be needed to provide the quantum leap that this broad technology is potentially capable of delivering
on. Synergies between bioinformatics, sequencing power, smart screening technologies, and synthetic
biology will provide the platform to drive biodiscovery for marine biocatalyst of the future. To achieve
this, and maximize its effectiveness, scientists from all disciplines will need to coordinate and cooperate
towards common and compatible goals. Expertise in informatics, molecular biology, chemistry,
drug design, physics, engineering, systems biology and other disciplines, incorporating both academic
and industrial partners will be best placed to address the challenges and provide the future platforms
for biocatalytic and natural product discovery.
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